Top News
CD73 Inhibitor-Based Triplet Induces Responses in Metastatic PDAC
EGFR Overexpression Without Amplification or Mutation Found to Be Common in Malignant Mesothelioma
Guidance on Lifestyle Factors Provided at a Lower Rate to Cancer Survivors
Narsoplimab Under Review for Stem Cell Transplant-Associated Thrombotic Microangiopathy
Carriers of CALR Mutations at Decreased Risk for Thrombotic Events Among Patients With Essential Thrombocythemia
Enhertu Gains Gastric Cancer Indication
Potential Med Errors Prompt FDA Action on Vinca Alkaloid Labeling
First Treatment for Newly Diagnosed Light Chain Amyloidosis Approved
In NSCLC, Many Small Cell Transformations Could Be Pseudo Transformations
Zanidatamab Active in HER2-Positive Biliary Tract Cancer
Study Data Suggest Role for Lenvatinib in Unresectable HCC With Child-Pugh B Liver Function
EDITORIAL ADVISORY BOARD
E. David Crawford, MD
Jeffrey M. Farma, MD
Featured
-
First GnRH Receptor Antagonist Enters Advanced Prostate Cancer Treatment Portfolio
Daniel J. George, MD, a lead investigator on the HERO study, discusses the implications of relugolix’s approval for advanced prostate cancer. -
Oral Contraceptives Found to Protect Against Ovarian and Endometrial Cancer for up to 35 Years After Discontinuation
Investigators of the observational study sought to clarify the time-dependent effects between long-term oral contraceptive use and risk for breast, ovarian, and endometrial cancer risk. -
Use of Commercial Genomic Testing for Prostate Cancer ‘Highly Variable’ in the United States
Investigators evaluated a large sample of commercially insured patients with prostate cancer to assess use of tissue-based gene expression testing. -
Lung SCC Highly Mutated yet Homogenous Across Diverse Demographic Populations
Investigators used next-generation sequencing to characterize the genomic profile of squamous cell carcinoma (SCC) in 26 Colombian patients with lung SCC. -
Biosimilars in Cancer Care: Insights From 2020 and Expectations for 2021
Sean McGowan, senior director of Biosimilars at AmerisourceBergen, and Brian Ansay, senior vice president of Sales and Corporate Services at ION Solutions, review 2020 biosimilar trends in oncology and forecast what is ahead in 2021. -
T-VEC Shows Promise as Neoadjuvant Therapy in Melanoma
Investigators compared recurrence-free survival and overall survival outcomes in patients randomly assigned to receive neoadjuvant talimogene laherparepvec (T-VEC) followed by immediate surgery or surgery alone. -
Sodium Bicarbonate Associated With Enhanced GVL Effect in AML Following Allo-HSCT
Investigators assessed sodium bicarbonate’s viability as a pharmacologic strategy in mouse models and humans with acute myeloid leukemia.
More Features
6 Emotional Health Concerns of Oncologists During the COVID-19 Pandemic
Researchers have found a concerning level of distress in oncologists as a result of the COVID-19 pandemic that needs to be addressed so that they can better treat their patients and safeguard their own mental health.
Expanded Access Programs Deliver Real-World Efficacy Data
Efficacy data from expanded access programs were reported at ASH 2020, but whether these data will inform regulatory decisions remains to be seen.
A Statistical Fallacy Might Mar Study Findings on Bevacizumab in Melanoma
“‘Trended strongly’ is code for ‘we failed to meet statistical significance,’” remarked one expert, when she was asked to scrutinize the conclusions of a recent post hoc analysis.
A Tool Meant to Catch Distress in Patients With Breast Cancer May Overlook the True Needs of Black Women
The pitfall of self-reported stress levels is that the baseline stress for some people is so high, a cancer diagnosis doesn’t even register.
Study Shows Convalescent Plasma Is Beneficial for COVID-19 Patients With Hematological Malignancies
Despite mixed evidence for the general population, cumulative research reveals dramatic improvement with convalescent plasma for blood cancer patients, especially when given early.
-
Loading...
-
Loading...
